Comparing the Safety and Efficacy of Apixaban and Rivaroxaban
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 10000 participants.
Also called NCT06953726
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 10,000 participants
- Registry
-
NCT06953726
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT06953726. Randomized; no masking; primary purpose treatment. Start 2026-06-01 (actual); primary completion 2032-10-04 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparing the Safety and Efficacy of Apixaban and Rivaroxaban
- Acronym
- VALIANT-AF-T
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Apixaban
- Intervention (Drug)
- Rivaroxaban
- Lead sponsor
- VA Office of Research and Development
- Collaborator
- Food and Drug Administration (FDA)
Record details
- Record id
cardio:ct-nct06953726- Content hash
bec9f46c18d37e20f912348f15bb1060460535d5bb5cc47328732baebc767e2a